Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03397329 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03397329 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT03397329, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this Phase 1, randomized, open-label, two-period crossover study is to characterize and compare the pharmacokinetic (PK) profiles and evaluate the safety of the AG-348 tablet and capsule formulations after single-dose administration in healthy adult subjects. Pharmacokinetic sampling will take place serially at specified times during conduct of the study.
Interventions
- DRUG AG-348 Sequence A
- DRUG AG-348 Sequence B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2017-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03397329
The ClinicalTrials.gov registry entry for NCT03397329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AG-348 Sequence A is the first listed.
NCT03397329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03397329 about?
NCT03397329 is a clinical study titled "Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults". The purpose of this Phase 1, randomized, open-label, two-period crossover study is to characterize and compare the pharmacokinetic (PK) profiles and evaluate the safety of the AG-348 tablet and capsule formulations after single-dose administration in healthy adult subjects. Pharmacokinetic sampling ...
What is the current status of trial NCT03397329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-10-03. Estimated completion is 2017-11-13.
What interventions are being tested in trial NCT03397329?
The interventions under investigation include: AG-348 Sequence A (DRUG), AG-348 Sequence B (DRUG).
Who is sponsoring clinical trial NCT03397329?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.